News from naurex inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 15, 2014, 07:30 ET

Naurex to Present at UBS Global Healthcare Conference

 Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, PhD, will present at the UBS Global Healthcare...

May 06, 2014, 07:30 ET

Naurex Reports Positive Top-Line Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous...

Mar 03, 2014, 07:30 ET

FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13

 Naurex Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of...

Feb 27, 2014, 07:30 ET

Naurex to Present at Cowen and Co. 34th Annual Health Care Conference

Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, Ph.D., will present at the Cowen and Company 34th...

Jan 09, 2014, 17:09 ET

Naurex to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of...

Jan 08, 2014, 08:00 ET

Naurex Names Dr. Norbert G. Riedel President and Chief Executive Officer

 Naurex Inc. today announced that Norbert G. Riedel, Ph.D., has been named president and chief executive officer effective January 1,...

Dec 12, 2013, 08:00 ET

Naurex Presents Data on Rapid-Acting Antidepressant GLYX-13 that Support Long-term Synaptic Plasticity as Its Mechanism of Action

 Naurex Inc. today announced the presentation of preclinical data at the 52nd Annual Meeting of the American College of Neuropsychopharmacology...

Jul 30, 2013, 07:30 ET

Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...

Jun 04, 2013, 07:30 ET

Naurex Announces Initiation Of Phase I Trial For Second-Generation Novel Antidepressant Agent NRX-1074

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...

Dec 17, 2012, 07:30 ET

Naurex Completes $38 Million Series B Financing

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...

Dec 06, 2012, 07:30 ET

Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported...

Nov 07, 2011, 08:00 ET

Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's 2011 Top 10 Neuroscience Projects to Watch

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today...

Jun 22, 2011, 07:30 ET

Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it...

May 11, 2011, 07:00 ET

Naurex Completes $18 Million Series A Financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...

Dec 07, 2010, 07:30 ET

New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data being...

Nov 17, 2010, 07:30 ET

Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms with Ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at...

Aug 31, 2010, 07:30 ET

Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical...

Jun 17, 2010, 11:25 ET

Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented...

Feb 10, 2010, 07:00 ET

Naurex Inc. Reports Positive Top-Line Phase I Results for Its Novel Mechanism NMDA Receptor Modulator GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site...

Dec 16, 2009, 07:45 ET

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge